Login to MyKarger

New to MyKarger? Click here to sign up.



Login with Facebook

Forgot your password?

Authors, Editors, Reviewers

For Manuscript Submission, Check or Review Login please go to Submission Websites List.

Submission Websites List

Institutional Login
(Shibboleth or Open Athens)

For the academic login, please select your country in the dropdown list. You will be redirected to verify your credentials.

High-Performance Membrane Dialyzers

Editor(s): Saito A. (Isehara) 
Kawanishi H. (Hiroshima) 
Yamashita A.C. (Fujisawa) 
Mineshima M. (Tokyo) 
Cover

High-Performance Membrane Dialyzers in Critical Care

Comparison of Efficacy between Continuous Hemodiafiltration with a PMMA High-Performance Membrane Dialyzer and a PAN Membrane Hemofilter in the Treatment of Septic Shock Patients with Acute Renal Failure

Matsuda K. · Moriguchi T. · Harii N. · Yanagisawa M. · Harada D. · Sugawara H.

Author affiliations

Department of Emergency and Critical Care Medicine, University of Yamanashi School of Medicine, Yamanashi, Japan

Related Articles for ""

Saito A, Kawanishi H, Yamashita AC, Mineshima M (eds): High-Performance Membrane Dialyzers. Contrib Nephrol. Basel, Karger, 2011, vol 173, pp 182–190

Do you have an account?

Login Information





Contact Information










I have read the Karger Terms and Conditions and agree.



Login Information





Contact Information










I have read the Karger Terms and Conditions and agree.



To view the fulltext, please log in

To view the pdf, please log in

Buy

  • FullText & PDF
  • Unlimited re-access via MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

CHF 38.00 *
EUR 35.00 *
USD 39.00 *

Select

KAB

Buy a Karger Article Bundle (KAB) and profit from a discount!

If you would like to redeem your KAB credit, please log in.


Save over 20% compared to the individual article price.
Learn more

Rent/Cloud

  • Rent for 48h to view
  • Buy Cloud Access for unlimited viewing via different devices
  • Synchronizing in the ReadCube Cloud
  • Printing and saving restrictions apply

Rental: USD 8.50
Cloud: USD 20.00


Select

Complete book

  • Immediate access to all parts of this book
  • Cover-to-cover formats may be available
  • Unlimited re-access via MyKarger
  • Unrestricted printing, no saving restriction for personal use
read more

Pricing depends on hard-cover price


Select

* The final prices may differ from the prices shown due to specifics of VAT rules.

Article / Publication Details

First-Page Preview
Abstract of High-Performance Membrane Dialyzers in Critical Care

Published online: August 08, 2011
Cover Date: 2011

Number of Print Pages: 9
Number of Figures: 3
Number of Tables: 1

ISBN: 978-3-8055-9812-5 (Print)
eISBN: 978-3-8055-9813-2 (Online)

Abstract

The aim of this study was to investigate whether continuous hemodiafiltration (CHDF) with a high-performance membrane dialyzer made of polymethylmethacrylate (PMMA-CHDF) in the treatment of septic shock patients with acute renal failure (ARF) is clinically relevant. 30 patients were treated with PMMA-CHDF. 13 patients treated with CHDF used a hemofilter made of polyacrylonitrile membrane (PAN-CHDF). Systolic blood pressure significantly increased in the PMMA-CHDF group following 24 h of treatment (p < 0.01), whereas it did not improve in the PAN-CHDF group. Urine volume significantly increased in the PMMA-CHDF group following 24 h of treatment which was more than in the PAN-CHDF group (p < 0.05). 28-day survival was 83.3% in the PMMA-CHDF group and 30.8% in the PAN-CHDF group, respectively (p < 0.01). We can assume that PMMA-CHDF in the treatment of septic shock patients with ARF is clinically relevant.

© 2011 S. Karger AG, Basel


References

  1. Ronco C Bellomo R Homel P Brendolan A Dan M Piccinni P La Greca G: Effects of different doses in continuous veno-venous haemofiltration on outcomes of acute renal failure: a prospective randomized trial. Lancet 2000; 355: 26-30
  2. Honore PM Joannes-Boyau O Merson L Boer W Piette V Galloy AC Janvier G: The big bang of hemofiltration: the beginning of a new era in the third millennium for extracorporeal blood purification!. Int J Artif Organs 2006; 29: 649-659
  3. Bellomo R: Do we know the optimal dose for renal replacement therapy in the intensive care unit?. Kidney Int 2006; 70: 1202-1204
  4. Hirasawa H Oda S Matsuda K: Continuous hemodiafiltration with cytokine-adsorbing hemofilter in the treatment of severe sepsis and septic shock. Contrib Nephrol Basel, Karger, 2007; vol 156: 365-370
  5. Nakada T Oda S Matsuda K Sadahiro T Nakamura M Abe R Hirasawa H: Continuous hemodiafiltration with PMMA hemofilter in the treatment of patients with septic shock. Mol Med 2008; 14: 257-263
  6. Matsuda K Moriguchi T Harii N Goto J: Comparison of efficacy between continuous hemodiafiltration with a PMMA membrane hemofilter and a PAN membrane hemofilter in the treatment of a patient with septic acute renal failure. Transfus Apher Sci 2009; 40: 49-53
  7. Matsuda K Moriguchi T Oda S Hirasawa H: Efficacy of continuous hemodiafiltration with a cytokine-adsorbing hemofilter in the treatment of acute respiratory distress syndrome. Contrib Nephrol Basel, Karger, 2010; vol 166: 83-92
  8. Nakamura M Oda S Sadahiro T Hirayama Y Watanabe E Tateishi Y Nakada TA Hirasawa H: Treatment of severe sepsis and septic shock by CHDF using a PMMA membrane hemofilter as a cytokine modulator. Contrib Nephrol Basel, Karger, 2010; vol 166: 73-82
  9. Honore PM Joannes-Boyaub O Gressensa B: Blood and plasma treatments: the rationale of high-volume hemofiltration. Contrib Nephrol Basel, Karger, 2007; vol 156: 387-395
  10. Members of the American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference Committee: American College of Chest Physicians/ Society of Critical Care Medicine Consensus Conference: Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med 1992; 20: 864-874
  11. Vincent JL de Mendonca A Cantraine F Moreno R Takala J Suter P Sprung CL Colardyn F Blecher S: Use of the SOFA score to assess the incidence of organ dysfunction/failure in intensive care units: results of a multicenter, prospective study. Crit Care Med 1998; 26: 1793-1800
  12. Knaus WA Draper EA Wagner DP Zimmerman JE: APACHE II: a severity of disease classification system. Crit Care Med 1985; 13: 818-829
  13. Matsuda K Hirasawa H Oda S Shiga H Nakanishi K: Current topics on cytokine removal technologies. Ther Apher 2001; 5: 306-314
  14. Haase M Silvester W Uchino S Goldsmith D Davenport P Tipping P Boyce N Bellomo R: A pilot study of high-adsorption hemofiltration in human septic shock. Int J Artif Organs 2007; 30: 108-117
  15. Hirasawa H Odaka M Kobayashi H Soeda K Kobayashi S Murotani N Ito Y Isono K: Hemopurification in the treatment of patients with multiple organ failure. (eds) Nose Y Kjellstrand C Ivanovich P: Progress in Artificial Organs, 1985 Cleveland, ISAO Press, 1986;730-734
  16. Stein B Pfenninger E Gruenert A Schmitz JE Hudde M: Influence of continuous haemofiltration on haemodynamics and central blood volume in experimental endotoxic shock. Intensive Care Med 1990; 16: 494-499
  17. Hirasawa H Sugai T Ohtake Y Oda S Matsuda K Kitamura N: Blood purification for prevention and treatment of multiple organ failure. World J Surg 1996; 20: 482-486
  18. Kellum JA: Immunomodulation in sepsis: the role of hemofiltration. Minerva Anestesiol 1999; 65: 410-418
  19. De Vriese AS Vanholder RC Pascual M Lameire NH Colardyn FA: Can inflammatory cytokines be removed efficiency by continuous renal replacement therapies?. Intensive Care Med 1999; 25: 903-910
  20. Rogiers P: Hemofiltration treatment for sepsis: is it time for controlled trials?. Kidney Int 1999; 72: ((suppl)) S99-S103
  21. Ronco C Bonello M Bordonia V Ricci Z D’Intini V Bellomo R Levin NW: Extracorporeal therapies in non-renal disease: treatment of sepsis and the peak concentration hypothesis. Blood Purif 2004; 22: 164-174
  22. Honore PM Joannes-Boyau O: High-volume hemofiltration in sepsis: a comprehensive review of rationale, clinical applicability, potential indications and recommendations for future research. Int J Artif Organs 2004; 27: 1077-1082
  23. Di Carlo JV Alexander SR: Hemofiltration for cytokine-driven illnesses: the mediator delivery hypothesis. Int J Artif Organs 2005; 28: 777-786
  24. Hirasawa H: Indications for blood purification in critical care. Contrib Nephrol Basel, Karger, 2010; vol 166: 21-30
  25. Busund R Koukline V Utrobin U Nedashkovsky E: Plasmapheresis in severe sepsis and septic shock: a prospective, randomised, controlled trial. Intensive Care Med 2002; 28: 1434-1439
  26. Piccinni P Dan M Barbacini S Carraro R Lieta E Marafon S Zamperetti N Brendolan A D’Intini V Tetta C Bellomo R Ronco C: Early isovolaemic haemofiltration in oliguric patients with septic shock. Intensive Care Med 2006; 32: 80-86
  27. Saudan P Niederberger M Seigneux SD Romand J Pugin J Perneger T Martin PY: Adding a dialysis dose to continuous hemofiltration increases survival in patients with acute renal failure. Kidney Int 2006; 70: 1312-1317
  28. House AA Ronco C: Extracorporeal blood purification in sepsis and sepsis-related acute kidney injury. Blood Purif 2008; 26: 30-35
  29. Joannidis M: Continuous renal replacement therapy in sepsis and multisystem organ failure. Semin Dial 2009; 22: 160-64
  30. Schefold JC Hasper D Jörres A: Organ crosstalk in critically ill patients: hemofiltration and immunomodulation in sepsis. Blood Purif 2009; 28: 116-123

Article / Publication Details

First-Page Preview
Abstract of High-Performance Membrane Dialyzers in Critical Care

Published online: August 08, 2011
Cover Date: 2011

Number of Print Pages: 9
Number of Figures: 3
Number of Tables: 1

ISBN: 978-3-8055-9812-5 (Print)
eISBN: 978-3-8055-9813-2 (Online)


Copyright / Drug Dosage / Disclaimer

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.